1. Introduction
Molecular targeted drugs and
immune checkpoint blockades have remarkably improved outcomes for
patients with advanced
non-small
cell lung cancer (NSCLC) (1, 2).
However, those drugs are not indicated for all advanced NSCLC cases. For
such patients, cytotoxic drugs are the main treatment, and the prognosis
remains poor.
Here, we report a patient with advanced non-squamous (non-Sq) NSCLC and
malignant pleural effusion who was treated with cytotoxic drugs:
cisplatin-based induction chemotherapy, followed by pemetrexed
maintenance therapy (PMT), to which she achieved a durable complete
response (CR) for six years to date, after discontinuing all drug
treatments.